ZICOM GROUP LIMITED — Capital/Financing Update 2012

Apr 30, 2012

ABN 62 009 816 871 Zicom Group Limited

==> picture [64 x 16] intentionally omitted <==

==> picture [64 x 16] intentionally omitted <==

==> picture [64 x 16] intentionally omitted <==

38 Goodman Place, Murarrie, Queensland 4172 • Tel: (07) 3908 6088 • Fax: (07) 3390 6898

30 April 2012

Market Announcement Office Australian Securities Exchange Level 6, 20 Bridge Street SYDNEY NSW 2000

Dear Sir,

BUSINESS UPDATE

The Group is pleased to announce the following business update:-

a) General Business Prospects

Business prospects as outlined in our Half Year’s Financial Report are expected to remain generally unchanged up to year ending 30 June 2012. The Profit Guidance given for the full year is expected to remain the same, although order intakes have improved slightly.

b) Outstanding Confirmed Orders

The following outstanding orders as at 31 March 2012 totalling S$46.9m showed a slight improvement over the outstanding orders of S$41.6m as at 31 December 2011:-

Marine Offshore, Oil & Gas Construction Equipment Precision Engineering & Automation Industrial & Mobile Equipment Total orders S$	S$m 22.3 6.8 17.6 0.2 46.9 m

Of these orders S$31.3m (31.12.2011: S$32.4m) are expected to be delivered within the remaining quarter of this financial year.

We believe that notwithstanding the uncertain global economic environment, barring no unforeseen circumstances, the Group expects to experience improvements in all sectors in the next financial year ending 30 June 2013.

c) Progress in Start-Up Investments

We are pleased to advise that except for BioBot Surgical Pte Ltd which has undergone a re-structuring, resulting in the removal of the Founder as a CEO in November 2011 and as a director on 28 February 2012, the commercialisation efforts for the other 3 start-up investments are expecting to take off in the next two months.

i)

Curiox Biosystems Pte Ltd (Curiox)

• Curiox has set up a subsidiary in San Francisco fully focused on the USA market identified as the market of greatest potentials for the Company. Curiox’s CEO is based full time there and together with his marketing and application teams, covers the markets in USA, Japan and Europe. Curiox’s patented DropArray technology has been endorsed and embraced by a few world leading renowned drug companies who are respected key opinion leaders. We expect sales of units to

1 Business Update 30 April 2012

materialise within this coming month. The technology is under-scored by a bioinstrumentation washing machine and microplates that enable drug discovery processes to achieve considerable savings in disease markers, reagents, and time spent over existing conventional methods.

To drive and ensure that its commercialization efforts gain quick momentum, Curiox has carried out a rights issue exercise to raise S$999,145.00. The Group is investing a further sum of S$905,974.00 increasing its shareholdings in Curiox from 41.36% to 46.50%. The investment is fully funded by the Group’s internal resources.

ii) Orion Systems Integration Pte Ltd (Orion)

After several months of rigorous trials in production runs and in-house testing, Orion has addressed all its customers’ identifiable needs to stay ahead of the competition curve. Orion is expected to secure its first customer for its fully commercialised unit within the next 2 months. Orion has developed a fine pitch flip chip thermal bonder with advanced features ahead of competitors for bonding high computing chips that are increasing in demand. The Group foresees further investment in Orion in the near future to help drive its commercialisation efforts. The Group is confident of being able to fund the investment internally.

iii) SAEdge Vision Solutions Pte Ltd (SAEdge)

SAEdge is manned by a team with established expertise in optics and vision and is positioned to sell vision systems to industries for automation. As a subsidiary to Sys-Mac Automation Engineering Pte Ltd (Sys-Mac), our wholly owned precision engineering subsidiary, SAEdge strengthens Sys-Mac’s automation capability as well as Orion’s technology. Orders for vision systems are foreseen within this coming quarter.

iv) BioBot Surgical Pte Ltd (BioBot)

Following the removal of the Founder-CEO, a younger team of engineers engaged in continuing to develop and improve on the iSR’obot surgical robot in close cooperation and collaboration with the clinicians of Singapore’s largest general hospital has achieved accelerated progress. Following these efforts, considerable technical improvements on the robot are being carried out and rigorously tested. Biobot aims to be able to begin commercialising its robot in the first quarter of calendar year 2013. Led by a new CEO and with a re-focused direction, Biobot has, since the removal of the Founder-CEO, reduced its monthly overheads by two thirds, expecting to achieve savings of an estimated S$1m for the next 12 months.

As BioBot’s funds have been completely depleted, the Company is issuing interest free convertible loan stocks to its shareholders to raise an initial amount of S$990,000.00. The loan stocks are convertible into shares of Biobot at S$0.30 per share on 1 July 2013. Attached to each loan stock is a warrant entitling the holders to subscribe for further shares at S$0.30 each by 31 December 2013 that could potentially raise another S$990,000 if the warrants are fully exercised. The Group has taken up 2,707,397 convertible loan stocks investing a further amount of S$812,219.00 into BioBot potentially raising its shareholdings from 46.67% to 56.16%. The investment is fully funded from the Group’s internal resources.

2 Business Update 30 April 2012

The Group does not expect the performance of the start-up investments as having any immediate impact on its 2012 results. It is confident that their contributions would be more evident from the financial year 2013 onwards.

The Group continues to take advantage of any opportunities for synergistic acquisitions as they arise.

Yours faithfully

ZICOM GROUP LIMITED

==> picture [36 x 50] intentionally omitted <==

-------------------------------G L Sim Chairman.

3 Business Update 30 April 2012